Extrovis

What Extrovis does

Extrovis AG is an Indo-Swiss global Contract Research, Development and Manufacturing Organization (CRDMO) headquartered in Baar, Switzerland, that develops and manufactures complex therapeutics for the world's pharmaceutical companies. The company is structured around five operating geographies: corporate headquarters in Switzerland, R&D centers in Hyderabad and Pune (India), manufacturing operations at Latina Pharma in Italy, Pharma Pack in Hungary, and the flagship Kavis Pharma facility in Sugar Land, Texas. As of 2026 it employs 750+ professionals, including 250+ R&D scientists across three continents, delivering against a portfolio that spans sterile antibiotics (cephalosporins APIs and dosage forms, monobactams), cytotoxic formulations across OEB 1-5 (oral solids, injectables, topicals, oral liquids), and female hormone products, alongside newer modalities such as drug-device combinations, peptides, and complex parenterals.

The company's core technology platform is its multi-jurisdictional manufacturing infrastructure accredited by US FDA, EU GMP, and PMDA, with dedicated segregated production lines for beta-lactams and engineered containment for high-potent compounds. R&D capabilities span formulation development, novel delivery systems, and advanced process analytical technologies, supporting delivery of 50+ dosage forms and 30+ drug substances from concept through commercialization. An integrated global supply chain serves 200+ SKUs across 50+ countries, with capabilities anchored in Research, Manufacturing, and Commercial functions.

Commercially, Extrovis operates a B2B enterprise contract services model, generating revenue through transaction fees on contract manufacturing and professional services fees on R&D and regulatory engagements. Pricing is quote-based and project-negotiated, tied to complexity, volume, and regulatory requirements, and is not publicly disclosed. The go-to-market motion targets both large global pharma companies and small biotech sponsors through long-term strategic alliances built on 'accountable collaboration models.' Distribution is exclusively direct, with no intermediary channels, supported by digital marketing (corporate website, LinkedIn, Facebook), email inquiry, and industry events. Registered sub-brands SOLARTUS and ADROIQ suggest pending branded product initiatives beyond core contract services.

Name

Extrovis

Legal name

Extrovis AG

Website

https://extrovis.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Extrovis AG is an Indo-Swiss global CRDMO headquartered in Switzerland that develops and manufactures complex therapeutics, including sterile antibiotics, cytotoxic formulations, peptides, and drug-device combinations, for global pharmaceutical companies across 50+ countries via a five-country manufacturing and R&D network.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

akta.pro secondary industries

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Contract pharmaceutical manufacturing
• Sterile injectables manufacturing
• Oncology drug development
• Active pharmaceutical ingredients
• Pharmaceutical formulation services

Headquarters

HQ city

Baar

HQ country

Switzerland

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: CDMO revenue from manufacturing drug substances and drug products for pharmaceutical partners. Services span from clinical development through commercial scale with regulated market supply. Revenue generated through project-based contracts with pharmaceutical companies for development and manufacturing services.
2. Contract Research Services: R&D services including formulation development, process design, and primary packaging for pharmaceutical companies. Global R&D organization delivers dosage forms and drug substances from concept through scale-up and regulatory approval.
3. Regulatory Services: Regulatory affairs support enabling faster approvals through compliant submissions. Expertise in country-specific requirements and filings for global market entry.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Extrovis is a global Contract Research, Development, and Manufacturing Organization (CRDMO) providing integrated pharmaceutical services from molecule to market. The company specializes in sterile antibiotics (APIs and dosage forms), cytotoxic oncology formulations (oral solids, injectables, topicals, oral liquids), and female hormone products. Services span formulation R&D, drug substance and drug product manufacturing, regulatory submissions, and global supply chain distribution across USFDA-, EU-GMP-, and PMDA-accredited facilities.

Product overview

Extrovis is an Indo-Swiss global CRDMO (Contract Research, Development & Manufacturing Organization) that operates as a unified platform offering integrated pharmaceutical development and manufacturing services. The company's portfolio comprises two core service lines: Drug Substances (Sterile Cephalosporins, High Potent Monobactams, Advanced Intermediates, and Controlled Substances) and Drug Products (Oncology Solids, Oncology Injectables, Oncology Topicals, Oncology Oral Liquids, Cephalosporin Injectable Vials, Cephalosporin Dual Chamber Bags, Female Hormone Topicals, Oral Liquids, and General Topicals). These capabilities are supported by R&D Services for formulation development and novel delivery systems, Manufacturing Services leveraging US FDA, EU GMP, and PMDA-accredited facilities, and Global Supply Chain Services covering 50+ markets with 200+ SKUs. The company specializes in high-impact therapeutic areas including oncology, sterile antibiotics and anti-infectives, and high-containment complex manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• SOLARTUS: Registered trademark of Extrovis AG and/or its affiliates.
• ADROIQ

Products and services

• Drug Substance Manufacturing Services

Quantifiable outcome

• Delivered 50+ dosage forms and 30+ drug substances from concept through commercialization
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature12 records

Scale indicators8 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Recipharm: European-headquartered CDMO with sterile fill-finish, API and oral solid dose capabilities — comparable in contract manufacturing scope, with a stronger European footprint and weaker India base.
• Syngene International: Bengaluru-based CRDMO providing API development, formulation and contract manufacturing to global pharma — comparable in Indo-global CRDMO model, though with a heavier discovery/CRO tilt than Extrovis.
• Piramal Pharma Solutions: India-headquartered global CDMO offering integrated drug substance and drug product development and manufacturing across sterile injectables, high-potency APIs and oral solids — directly comparable to Extrovis' CRDMO service mix and Indo-Swiss positioning.
• Sai Life Sciences: India-based CRDMO offering API, intermediate and formulation services to global innovator and generic pharma — directly comparable small-molecule development and manufacturing capability to Extrovis.
• Hikal: Indian CRDMO with API, intermediates and custom manufacturing across therapeutics including cephalosporins — directly comparable in geographic mix and small-molecule/API focus.
• Jubilant Pharmova: India-listed pharma company with a CDMO segment covering sterile injectables, APIs and radiopharmaceuticals — comparable in Indo-global CRDMO model with regulated-market supply.
• WuXi STA (WuXi AppTec): China-based global CRDMO with end-to-end API and drug product services across small molecules, peptides and complex injectables — directly comparable CRDMO service model, though currently exposed to US BIOSECURE-related headwinds.

Broad incumbents

• Lonza: Swiss-headquartered global CDMO leader across small molecules, biologics and cell/gene therapy — overlaps with Extrovis on small-molecule API and drug product, but at materially larger scale and broader modality coverage.
• Aurobindo Pharma: Large Indian generics manufacturer with growing CMO/CDMO services across APIs, injectables and cephalosporins — comparable in therapeutic focus but operates as a broad incumbent with much larger revenue base than Extrovis.
• Catalent: Global CDMO leader in softgel, oral and biologics fill-finish — overlapping capabilities in complex drug product development but with a much broader portfolio and recent Novo Holdings take-private.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/extrovis-pvt-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Extrovis